Key result
Higher myocardial MARK4 expression correlates with lower LVEF and sleep-disordered breathing.
Why the study?
MARK4 dysregulation is linked to impaired contractility in animal models, but MARK4 had not yet been investigated in the failing human heart.
Observational (n=152)
Myocardial MARK4 expression is increased in patients with impaired cardiac contractility and sleep-disordered breathing, suggesting it as a potential molecular target in heart failure.
Answers are grounded in this paper and cite their sources.
MARK4 expression may link sleep-disordered breathing to reduced contractility; leaves open whether targeting it could improve heart failure outcomes.
Background Heart failure is the leading cause of morbidity and mortality worldwide, highlighting the urgent need for new therapeutic targets and strategies. MARK4, a serine/threonine protein kinase, is involved in the regulation of microtubules. In cardiomyocytes, MARK4 dysregulation has been linked to increased cardiomyocyte stiffness and impaired contractility. Animal models of heart failure revealed a negative correlation between MARK4 levels and cardiac contractility. However, MARK4 has not yet been investigated in the failing human heart. Purpose This study aimed to investigate the myocardial MARK4 expression in cardiovascular high-risk patients and to assess its association with cardiac function and sleep-disordered breathing (SDB), a highly prevalent comorbidity in heart failure. Methods We analyzed myocardial biopsies of 152 cardiovascular high-risk patients undergoing cardiac surgery (Figure 1, left part). Comprehensive echocardiography as well as testing for SDB with polygraphy were performed preoperatively. SDB was diagnosed by an apnea/hypopnea index ≥ 15/h. MARK4 mRNA expression was quantified using qPCR and it is reported as percentage of the housekeeper β-actin (ACTB). MARK4 levels above the median were considered as increased. Results We observed a significantly increased MARK4 expression in patients with an impaired left ventricular ejection fraction (LVEF; Figure 1, upper right). Accordingly, the LVEF correlated inversely with MARK4 expression (β = -0.044, 95% confidence interval (CI): -0.059 to -0.030, p < 0.001). Moreover, MARK4 expression levels correlated with E/e’ (β = 0.067, 95% CI: 0.003 to 0.131, p = 0.040), a central parameter of diastolic dysfunction. Mechanistically, MARK4 levels were increased in SDB and under hypoxic conditions (Figure 1, lower right), as evidenced by significant correlations between myocardial MARK4 expression and factors like the mean oxygen saturation (β = -0.200, 95% CI: -0.260 to -0.139, p < 0.001), the time with nocturnal oxygen saturation < 90% (β = 0.028, 95% CI: 0.021 to 0.036, p < 0.001), and the oxygen desaturation index (β = 0.024, 95% CI: 0.014 to 0.033, p < 0.001). Multivariable regression analysis confirmed that both the LVEF and the mean oxygen saturation were independently associated with dysregulated MARK4 levels, even when controlling for important clinical covariables as potential confounders (Figure 2). Conclusion Taken together, our findings demonstrate that MARK4 expression is increased in patients with impaired cardiac contractility and SDB. This suggests MARK4 as a potential molecular target against cardiovascular diseases, which we will test in future studies.MARK4_Figure1 MARK4_Figure2
No takes yet. Share an insight, caveat, or question.
Seydel et al. (2025) conducted an observational in Cardiovascular high-risk patients (n=152). Myocardial MARK4 expression was evaluated on Correlation between left ventricular ejection fraction (LVEF) and MARK4 expression (β = -0.044, 95% CI -0.059 to -0.030, p=< 0.001). Myocardial MARK4 expression was inversely correlated with left ventricular ejection fraction and associated with sleep-disordered breathing.
Synapse has enriched 10 related papers. Consider them for comparative context: